Atengen’s novel therapeutic target is expressed specifically in tumor blood vessels of most types of solid tumors but not in the blood vessels of healthy organs. Our scientists have used innovative technologies to identify several drug candidates that not only suppress tumor growth by inhibiting new blood vessel growth, but also cause extensive tumor necrosis by killing existing tumor blood vessels. In targeting the tumor blood supply rather than the tumor cells themselves, we can kill solid tumors in a tissue agnostic manner, while still maintaining a high degree of specificity. This groundbreaking approach has the potential to revolutionize the treatment of solid tumors.
Company Details
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.atengen.com
Atengen, Inc. Questions
Atengen, Inc.'s website is http://www.atengen.com
Atengen, Inc.'s LinkedIn profile is https://www.linkedin.com/company/atengen-inc
Atengen, Inc.'s industry is
Biotechnology Research
Atengen, Inc.'s top competitors are
Orano Med,
Fuse Biotherapeutics,
Nkgen Biotech, Inc.,
Abcentra,
Nexcella, Inc.,
Immix Biopharma (Nasdaq: Immx),
Kairos Pharma Ltd. (Nyse: Kapa),
Kairos Pharma,
Gilead Sciences,
Kyverna Therapeutics.
Atengen, Inc.'s categories are Biotechnology Research
